128 related articles for article (PubMed ID: 37490605)
1. Assessing the relationship between antipsychotic drug use and prolidase enzyme activity and oxidative stress in schizophrenia patients: a case-control study.
Yazla E; Cetin I; Kayadibi H
Int Clin Psychopharmacol; 2023 Nov; 38(6):394-401. PubMed ID: 37490605
[TBL] [Abstract][Full Text] [Related]
2. Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects.
Choi KH; Higgs BW; Weis S; Song J; Llenos IC; Dulay JR; Yolken RH; Webster MJ
BMC Psychiatry; 2009 Sep; 9():57. PubMed ID: 19758435
[TBL] [Abstract][Full Text] [Related]
3. Blood-based oxidation markers in medicated and unmedicated schizophrenia patients: A meta-analysis.
Goh XX; Tang PY; Tee SF
Asian J Psychiatr; 2022 Jan; 67():102932. PubMed ID: 34839098
[TBL] [Abstract][Full Text] [Related]
4. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
5. Serum prolidase activity and oxidant-antioxidant status in children with chronic hepatitis B virus infection.
Şen V; Uluca Ü; Ece A; Kaplan İ; Bozkurt F; Aktar F; Bağlı S; Tekin R
Ital J Pediatr; 2014 Nov; 40():95. PubMed ID: 25425101
[TBL] [Abstract][Full Text] [Related]
6. Relationship between long-term use of a typical antipsychotic medication by Chinese schizophrenia patients and the bone turnover markers serum osteocalcin and β-CrossLaps.
Zhang B; Deng L; Wu H; Lu X; Peng L; Wu R; Guo W; Chen J; Li L; Zhao J
Schizophr Res; 2016 Oct; 176(2-3):259-263. PubMed ID: 27377977
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
8. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics.
Dakhale G; Khanzode S; Khanzode S; Saoji A; Khobragade L; Turankar A
Neuropsychobiology; 2004; 49(4):205-9. PubMed ID: 15154399
[TBL] [Abstract][Full Text] [Related]
9. Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case-control study.
Jorgensen A; Knorr U; Soendergaard MG; Lykkesfeldt J; Fink-Jensen A; Poulsen HE; Jorgensen MB; Olsen NV; Staalsø JM
BMC Psychiatry; 2015 Apr; 15():67. PubMed ID: 25880260
[TBL] [Abstract][Full Text] [Related]
10. Serum prolidase and oxidative stress levels in patients with recurrent aphthous stomatitis: a prospective, controlled study.
Ekinci A; Demir E; Ekinci H
Indian J Dermatol Venereol Leprol; 2020; 86(1):18-23. PubMed ID: 31249217
[TBL] [Abstract][Full Text] [Related]
11. A defect in the antioxidant defense system in schizophrenia.
Virit O; Altindag A; Yumru M; Dalkilic A; Savas HA; Selek S; Erel O; Herken H
Neuropsychobiology; 2009; 60(2):87-93. PubMed ID: 19776652
[TBL] [Abstract][Full Text] [Related]
12. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia.
Dakhale GN; Khanzode SD; Khanzode SS; Saoji A
Psychopharmacology (Berl); 2005 Nov; 182(4):494-8. PubMed ID: 16133138
[TBL] [Abstract][Full Text] [Related]
13. Serum prolidase enzyme activity in obese subjects and its relationship with oxidative stress markers.
Aslan M; Duzenli U; Esen R; Soyoral YU
Clin Chim Acta; 2017 Oct; 473():186-190. PubMed ID: 28867357
[TBL] [Abstract][Full Text] [Related]
14. Associations of oxidative stress status parameters with traditional cardiovascular disease risk factors in patients with schizophrenia.
Vidović B; Stefanović A; Milovanović S; Ðorđević B; Kotur-Stevuljević J; Ivanišević J; Miljković M; Spasić S
Scand J Clin Lab Invest; 2014 Apr; 74(3):184-91. PubMed ID: 24446766
[TBL] [Abstract][Full Text] [Related]
15. Molindone for schizophrenia and severe mental illness.
Bagnall A; Fenton M; Lewis R; Leitner ML; Kleijnen J
Cochrane Database Syst Rev; 2000; (2):CD002083. PubMed ID: 10796464
[TBL] [Abstract][Full Text] [Related]
16. The effects of atypical and conventional antipsychotics on reduced processing speed and psychomotor slowing in schizophrenia: a cross-sectional exploratory study.
Morrens M; Hulstijn W; Sabbe B
Clin Ther; 2008 Apr; 30(4):684-92. PubMed ID: 18498917
[TBL] [Abstract][Full Text] [Related]
17. Prolidase activity and oxidative stress in patients with schizophrenia: a preliminary study.
Bahceci B; Bagcioglu E; Kokacya MH; Dilek AR; Bahceci I; Selek S
J Pak Med Assoc; 2015 Feb; 65(2):131-5. PubMed ID: 25842545
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment.
Gebhardt S; Härtling F; Hanke M; Mittendorf M; Theisen FM; Wolf-Ostermann K; Grant P; Martin M; Fleischhaker C; Schulz E; Remschmidt H
Eur Child Adolesc Psychiatry; 2006 Oct; 15(7):371-82. PubMed ID: 16648965
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment.
Güneş M; Camkurt MA; Bulut M; Demir S; İbiloğlu AO; Kaya MC; Atlı A; Kaplan İ; Sir A
Clin Psychopharmacol Neurosci; 2016 Nov; 14(4):345-350. PubMed ID: 27776386
[TBL] [Abstract][Full Text] [Related]
20. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
